ProCE Banner Activity

A New Regimen for Advanced HCC: Atezolizumab Plus Bevacizumab

Clinical Thought
Atezolizumab plus bevacizumab was recently approved as first-line systemic therapy for patients with advanced HCC. Read an expert’s thoughts how this new approach will fit into contemporary treatment paradigms.

Released: September 15, 2020

Expiration: September 14, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Eisai

Exelixis, Inc.

Genentech, a member of the Roche Group

Lilly

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Richard S. Finn, MD

Assistant Professor of Medicine
Division of Hematology-Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Richard Finn, MD, has disclosed that he has received consulting fees from AstraZeneca, Bayer, Bristol-Myers Squibb, CStone, Eisai, Lilly, Merck, Pfizer, and Roche/Genentech.